ReviewJournal of Korean medical science2025
Antimicrobial Resistance - The 'Real' Pandemic We Are Unaware Of, Yet Nearby.
Review in Journal of Korean medical science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- End-of-Life Antibiotic Use After the Life-Sustaining Treatment Decisions Act in Korea.JAMA network open · 2026Article
- Urinary Tract Infections: Etiology and Emerging Therapeutic Approaches.Antibiotics (Basel, Switzerland) · 2026Review
- Optimizing Antibiotic Use for Urinary Tract Infections: A Qualitative Assessment of Regular Prescribing Practices.Yonsei medical journal · 2026Article
- Antimicrobial Resistance Profiles of Bacteria Isolated from the Animal Health Sector in Zambia (2020-2024): Opportunities to Strengthen Antimicrobial Resistance Surveillance and Stewardship Programs.Antibiotics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Antimicrobial resistance (AMR) represents a persistent and escalating public health crisis, often overlooked despite its severe global impact. Unlike acute infectious diseases, AMR progresses silently but relentlessly, posing long-term threats to health systems worldwide. This review examines the historical evolution and current epidemiology of multidrug-resistant organisms (MDROs), emphasizing the global and Korean burden of MDROs. While the development of new antibiotics remains limited, alternative therapies such as bacteriophage treatment have re-emerged as potential solutions. However, challenges in access to novel agents persist, particularly in Korea, due to regulatory, economic, and market-related barriers. To counter AMR, comprehensive strategies are essential. These include infection control, antibiotic stewardship programs (ASPs), and the development and proper allocation of new drugs. The One Health approach must integrate human, animal, and environmental health perspectives. Notably, infectious disease specialists play a central role in this fight: leading ASPs, shaping policy, engaging in public education, supporting research, and coordinating multidisciplinary collaboration. The AMR pandemic is unlikely to subside without systemic reform, sustained investment, and international cooperation. Urgent efforts must be made to address this hidden but growing threat. Recognizing AMR as a true pandemic is the first step toward containing its spread and securing the efficacy of antibiotics for future generations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.